Effects of growth hormone administration in pediatric renal allograft recipients |
| |
Authors: | Sharon Bartosh Bruce Kaiser Iraj Rezvani Martin Polinsky Seth Schulman JoAnn Palmer H. J. Baluarte |
| |
Affiliation: | (1) Division of Pediatric Nephrology, St. Christopher's Hospital for Children and Temple University School of Medicine, Philadelphia, USA;(2) Present address: Department of Pediatric Nephrology, Wyler Children's Hospital, The University of Chicago Pritzker School of Medicine, 60637 Chicago, IL, USA |
| |
Abstract: | The efficacy of recombinant human growth hormone (rGH) was assessed in five pediatric allograft recipients with severe growth retardation despite successful renal transplants. rGH 0.05 mg/kg per dose was given six times weekly by subcutaneous injection to five prepubertal children (mean age 15.2±2.0 years) all of whom had bone ages less than or equal to 12 years (10.0±1.4 years), a height standard deviation score of less than –2.5 (–4.9±1.5), no evidence of catch-up growth, a calculated glomerular filtration rate (GFR) of more than 40ml/min per 1.73 m2 (51±6.8 ml/min per 1.73 m2), and stable renal function on alternate-day prednisone (16.7±2.6 mg/m2 per dose). Growth hormone profiles were abnormal in all children before treatment. rGH administration led to a significant increase in both growth rate (3.5±1.6 cm/year pre therapy, 8.5±1.4 cm/year post therapy,P<0.001) and percentage of expected growth velocity for bone age (67±31% pre therapy, 163±27% post therapy,P<0.001) with evidence of true catch-up growth. During the study period, three children had the appearance of secondary sexual characteristics, and one had premature advancement of his bone age. GFR decreased in three children, and in one rGH was discontinued due to a steady rise in serum creatinine. No significant changes were seen in serum calcium, phosphorus, cholesterol, triglycerides, glucose, or thyroid function, although a significant increase in alkaline phosphatase was found. In summary, growth-retarded pediatric renal allograft recipients may have abnormal endogenous GH production and respond favorably to rGH. The potential risk of deterioration in renal function due to rGH-induced hyperfiltration must be investigated. |
| |
Keywords: | Growth hormone Growth after renal transplantation Pediatric renal transplantation |
本文献已被 SpringerLink 等数据库收录! |
|